SMid Biotechnology Analyst Cheng, along with Dr. Curtis Chong, Clinical Asst Professor of Medical Oncology at Stanford, provide perspectives on the key players in Platinum Resistant Ovarian Cancer (Mersana Therapeutics & ImmunoGen) on an Analyst/Industry conference call to be held on April 12 at 11 am. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRSN:
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- J.P. Morgan Suggests 2 Stocks to Buy, Including One With 140% Upside Potential
- Mersana Therapeutics upgraded to Overweight from Neutral at JPMorgan
- Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial
- Mersana Therapeutics announces clinical hold on XMT-2056 Phase 1 trial